BioPharma Dive November 13, 2024
Kristin Jensen

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of obesity treatments.

Dive Brief:

  • Metsera, already a well-funded biotech startup, added another $215 million to its coffers as investors responded to the promise of its obesity drug pipeline.
  • Wellington Management and Venrock Healthcare Capital Partners led the latest round of financing, the company said Wednesday. New investors included “crossover” investors such as Fidelity Management & Research, Janus Henderson Investors and T. Rowe Price.
  • The Series B financing brings the total raised for Metsera to more than $500 million. The company officially launched in April after raising $290 million in a financing led by Arch Venture Partners and Population Health...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Related Articles:
Reflecting on a milestone year for cell and gene therapies
Pharma Pulse 3/3/25: Will Tariffs Affect Branded Drug Prices? Pharmacists' Role in Medical Cannabis Counseling and Patient Education & more
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs
Pharma’s Role in Ensuring Patient Access to Trustworthy Health Insights
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic

Share This Article